Meridian Bioscience Inc (NASDAQ:VIVO) files its latest 10-K with SEC for the fiscal year ended on September 30, 2017. Meridian Bioscience Inc is an integrated life science company. It is engaged in development, manufacture, sale and distribution of diagnostic test kits for certain gastrointestinal, viral, respiratory and parasitic infectious diseases. Meridian Bioscience Inc has a market cap of $614.054 million; its shares were traded at around $14.55 with a P/E ratio of 28.52 and P/S ratio of 3.11. The dividend yield of Meridian Bioscience Inc stocks is 3.44%. Meridian Bioscience Inc had annual average EBITDA growth of 4.50% over the past ten years. GuruFocus rated Meridian Bioscience Inc the business predictability rank of 4-star.
For the last quarter Meridian Bioscience Inc reported a revenue of $49.7 million, compared with the revenue of $47.00 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $200.8 million, an increase of 2.4% from last year. For the last five years Meridian Bioscience Inc had an average revenue growth rate of 2.6% a year.
The reported diluted earnings per share was 51 cents for the year, a decline of 32.9% from the previous year. Over the last five years Meridian Bioscience Inc had an average EPS decline of 7.6% a year. The Meridian Bioscience Inc had a decent operating margin of 18.62%, compared with the operating margin of 26.2% a year before. The 10-year historical median operating margin of Meridian Bioscience Inc is 28.66%. The profitability rank of the company is 8 (out of 10).
At the current stock price of $14.55, Meridian Bioscience Inc is traded at 36.9% discount to its historical median P/S valuation band of $23.07. The P/S ratio of the stock is 3.11, while the historical median P/S ratio is 4.96. The intrinsic value of the stock is $5.46 a share, according to GuruFocus DCF Calculator. The stock lost 11.21% during the past 12 months.
For the complete 20-year historical financial data of VIVO, click here.
